Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1-positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study

Kenichi Sakamoto; Norio Shiba; Takao Deguchi; Nobutaka Kiyokawa; Yoshiko Hashii; Akiko Moriya-Saito; Daisuke Tomizawa; Takashi Taga; Soichi Adachi; Keizo Horibe; Toshihiko Imamura

doi:10.1111/bjh.16080

Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1-positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study

Br J Haematol. 2019 Nov;187(3):372-376. doi: 10.1111/bjh.16080. Epub 2019 Jun 27.

Authors

Kenichi Sakamoto^{1

2

3}, Norio Shiba⁴, Takao Deguchi⁵, Nobutaka Kiyokawa⁶, Yoshiko Hashii⁷, Akiko Moriya-Saito³, Daisuke Tomizawa², Takashi Taga⁸, Soichi Adachi⁹, Keizo Horibe³, Toshihiko Imamura^{1

3}

Affiliations

¹ Department of Paediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
² Division of Leukaemia and Lymphoma, Children's Cancer Centre, National Centre for Child Health and Development, Tokyo, Japan.
³ National Hospital Organization, Clinical Research Centre, Nagoya Medical Centre, Nagoya, Japan.
⁴ Department of Paediatrics, Graduate School of Medicine, Yokohama City University Hospital, Yokohama, Japan.
⁵ Department of Paediatrics, Mie University Graduate School of Medicine, Mie, Japan.
⁶ Department of Paediatric Haematology and Oncology Research, National Centre for Child Health and Development, Tokyo, Japan.
⁷ Department of Paediatrics, Osaka University, Osaka, Japan.
⁸ Department of Paediatrics, Shiga Medical University, Otsu, Japan.
⁹ Department of Human Health Science, Kyoto University, Kyoto, Japan.

PMID: 31247675
DOI: 10.1111/bjh.16080

Abstract

We performed a retrospective analysis of leukaemic surface antigen expression and genomic data from a total of 100 RUNX1-RUNX1T1-positive paediatric acute myeloid leukaemia (AML) patients enrolled in the Japanese Paediatric Leukaemia/Lymphoma Study Group (JPLSG) AML-05 protocol to determine risk factors for relapse. In univariate analysis, the KIT exon 17 mutation (n = 21) and CD19 negativity (n = 59) were significant risk factors for relapse (P = 0·01). In multivariate analysis, CD19 negativity was the sole significant risk factor for relapse (hazard ratio, 3·09; 95% confidence interval, 1·26-7·59; P < 0·01), suggesting that biological differences between CD19-positive and CD19-negative RUNX1-RUNX1T1 AML patients should be investigated.

Keywords: RUNX1-RUNX1T1; CD19; acute myeloid leukaemia.

Publication types

Clinical Trial
Multicenter Study

MeSH terms

Adolescent
Antigens, CD19 / biosynthesis*
Child
Child, Preschool
Core Binding Factor Alpha 2 Subunit / biosynthesis*
Disease-Free Survival
Female
Gene Expression Regulation, Leukemic*
Humans
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / metabolism
Leukemia, Myeloid, Acute / mortality*
Leukemia, Myeloid, Acute / therapy
Male
RUNX1 Translocation Partner 1 Protein / biosynthesis*
Survival Rate

Substances

Antigens, CD19
CD19 molecule, human
Core Binding Factor Alpha 2 Subunit
RUNX1 Translocation Partner 1 Protein
RUNX1 protein, human
RUNX1T1 protein, human